Bristol-Myers, Otsuka slapped with Abilify suit; Roche said to drop idea of Chugai bid;

Pharma News

@FiercePharma: Top-read over the weekend: Pfizer eyes Actavis in backup plan to another AstraZeneca bid. More | Follow @FiercePharma

@TracyStaton: Novo Nordisk CEO on the house that Victoza built and the future of diabetes R&D. Article via FierceBiotech | Follow @TracyStaton

@EricPFierce: As EvaluatePharma figures, 2014 could rival 2009 in M&A action, and that is a lot. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Valeant, Ackman pass threshold to call pivotal Allergan meeting. Story | Follow @CarlyHFierce

> Bristol-Myers ($BMY) and its Abilify partner Otsuka were sued in New York by a patient claiming that the companies failed to properly warn doctors that the antipsychotic hikes the risk of diabetes in children. Report

> Roche ($RHHBY), which announced an $8.6 billion deal for InterMune ($ITMN) over the weekend, is said to have decided against bidding for the share of Japan's Chugai that it doesn't already own. Report

> India's government put all state-owned hospitals under review for "systemic corruption," including gifts from drugmakers designed to promote prescribing of their products. Report

> China's Luye Pharmaceutical minted a new billionaire--its chairman, Liu Dianbo--after strong first-half results sent its stock soaring. Report

> Since President Obama railed against companies looking for tax-inversion deals, such as Pfizer ($PFE) with its AstraZeneca ($AZN) bid, no companies have announced a buyout that relies on this sort of tax savings. Report

> Argentina, a key Latin American market for pharma, has added Indian drugmakers to its list of approved suppliers. Report

Medical Device News

@FierceMedDev: ICYMI:  approves more innovative med tech, faster in first half. Story | Follow @FierceMedDev

@VarunSaxena2: Covidien acquisition of Reverse Medical illustrates vascular device focus. Article | Follow @VarunSaxena2

@EmilyWFierce: $MDT shareholders rail against company's pending merger with $COV. Story via Pioneer Press | Follow @EmilyWFierce

> Chinese physicians implant first 3-D printed vertebrae in child. Story

> Endo reported to be selling its AMS med-dev unit. Article

> FDA approves more innovative med tech, faster in first half. More

Biotech News

@FierceBiotech: Roche extends biotech shopping spree with $8.3B InterMune buyout. News | Follow @FierceBiotech

@JohnCFierce: Getting the feeling today that the slower summer news cycle is coming to a close. | Follow @JohnCFierce

@EmilyMFierce: ICYMI: UCSF spinout launches crowdfunding campaign for Ebola drug. Story | Follow @EmilyMFierce

> Allergic reactions force Regado to pull the plug on PhIII anticoagulant study. Story

> J&J snaps up Covagen and its protein-antibody fusion platform. News

> Merck and Advaxis forge another no-money-down IO development pact. Article

CRO News

> Quintiles and Illumina look to jump-start cancer R&D with genomics sweepstakes. Article

> Evotec teams up with malaria nonprofit in open R&D project. Report

> Parexel: Biotech's boom pays dividends for CROs. More

> CRO PharPoint signs up to get Otologic's hearing drug into the clinic. Story

> Clinverse reels in a $9.1M funding round to expand its trial tech. Article

Biotech IT News

> Illumina teams with AstraZeneca, J&J and Sanofi on cancer diagnostic. More

> Rollout of openFDA continues with drug labeling, medtech adverse event APIs. Article

> Clinverse and Comprehend raise $30M in separate financing rounds. More

> uBiome raises $4.5M as first batch of Y Combinator biotechs pitch to investors. Story

> Rock Health backs cloud-based R&D platform as Abbott comes on board. Article

Animal Health News

> Merck releases tilapia vaccine. News

> China's Skystar Bio-Pharmaceutical sees revenue grow 25%. Report

> FDA warns Kentucky drug compounder after sick, dead horses reported. Article

> Boehringer Ingelheim's Vetmedica to open $30M facility near Kansas City. Story

> Kinavet CA-1 moves forward to trials. Item

And Finally... Medical advances have taken a bite out of the blood-products business, as the need for transfusions has declined by almost one-third over the past 5 years. Report

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.